Recombinant toxins for the treatment of cancer

Current Opinion in Molecular Therapeutics

Volumn 5, Issue 1, 2003, Pages 44-51

  Kreitman, Robert J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CTCL; Denileukin diftitox; Diphtheria toxin; Hairy cell leukemia; Monoclonal antibody; Pseudomonas exotoxin

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; BL 22; BUTYRIC ACID DERIVATIVE; CD22 ANTIGEN; CLADRIBINE; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IMMUNOTOXIN; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; PE 38; PENTOSTATIN; POKEWEED ANTIVIRUS PROTEIN; PSEUDOMONAS EXOTOXIN; RICIN; RICIN A; RITUXIMAB; STEROID; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; BODY WEIGHT DISORDER; BONE PAIN; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; FEVER; GASTROINTESTINAL TOXICITY; GENETIC ENGINEERING; HAIRY CELL LEUKEMIA; HALF LIFE TIME; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; LIGAND BINDING; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG EDEMA; MAXIMUM PERMISSIBLE DOSE; NONHUMAN; PROTEIN SYNTHESIS; REVIEW; SKIN LYMPHOMA; T CELL LYMPHOMA; TARGET CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DIPHTHERIA TOXIN; HUMANS; IMMUNOTOXINS; INTERLEUKIN-2; LEUKEMIA, HAIRY CELL; NEOPLASMS; RECOMBINANT PROTEINS;

BACTERIA (MICROORGANISMS); PHYTOLACCACEAE; PSEUDOMONAS;

EID: 0037299714     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Akhtar S, Maghfoor I: Rituximab plus CHOP for diffuse large-B-cell lymphoma. N Engl J Med (2002) 346(23):1830-1831.
2. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood (2002) 99(10):3554-3561.
3. Cheson B: Bexxar (Corixa/GlaxoSmithKline). Curr Opin Investig Drugs (2002) 3(1):165-170.
4. Alcindor T, Witzig TE: Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma. Curr Treat Options Oncol (2002) 3(4):275-282.
5. Yamaizumi M, Mekada E, Uchida T, Okada Y: One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell (1978) 15(1):245-250.
6. Eiklid K, Olsnes S, Pihl A: Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp Cell Res (1980) 126(2):321-326.
7. Endo Y, Mitsui K, Motizuki M, Tsurugi K: The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28S ribosomal RNA caused by the toxins. J Biol Chem (1987) 262(12):5908-5912.
8. Zamboni M, Brigotti M, Rambelli F, Montanaro L, Sperti S: High pressure liquid chromatographic and fluorimetric methods for the determination of adenine released from ribosomes by ricin and gelonin. Biochem J (1989) 259(3):639-643.
9. Carroll SF, Collier RJ: Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. J Biol Chem (1987) 262(18):8707-8711.
10. Uchida T, Pappenheimer AM Jr, Harper AA: Reconstitution of diphtheria toxin from two nontoxic cross-reacting mutant proteins. Science (1972) 175(24):901-903.
11. Uchida T, Pappenheimer AM Jr, Greany R: Diphtheria toxin and related proteins. I. Isolation and properties of mutant proteins serologically related to diphtheria toxin. J Biol Chem (1973) 248(11):3838-3844.
12. Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blattler WA, Taylor JA et al: Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion. Blood (1992) 79(3):576-585.
13. Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramilo O et al: A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood (1993) 82(9):2624-2633.
14. Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, Herdt J, Kopp WC, Rager H, Steinberg SM, Ghetie V et al: Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study. Blood (1995) 85(12):3457-3465.
15. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I: Treatment of advanced solid tumors with immunotoxin LMB-1: An antibody linked to Pseudomonas exotoxin. Nat Med (1996) 2(3):350-353.
16. Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, Strom TB, Murphy JR: Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-relatad interleukin-2 fusion protein. Protein Eng (1987) 1(6):493-498.
17. Chaudhary VK, FitzGerald DJ, Adhya S, Pastan I: Activity of a recombinant fusion protein between transforming growth factor type-α and Pseudomonas toxin. Proc Natl Acad Sci USA (1987) 84(13):4538-4542.
18. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I: A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature (1989) 339(6223):394-397.
19. Hwang J, FitzGerald DJ, Adhya S, Pastan I: Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell (1987) 48(1):129-136.
20. Allured VS, Collier RJ, Carroll SF, McKay DB: Structure of exotoxin A of Pseudomonas aeruginosa at 3.0 Ångstrom resolution. Proc Natl Acad Sci USA (1986) 83(5):1320-1324.
21. Rolf JM, Gaudin HM, Eidels L: Localization of the diphtheria toxin receptor-binding domain to the carboxyl-terminal Mr ∼ 6000 region of the toxin. J Biol Chem (1990) 265(13):7331-7337.
22. 194. J Biol Chem (1990) 265(33):20673-20677.
23. McKee ML, FitzGerald DJ: Reduction of furin-nicked Pseudomonas exotoxin A: An unfolding story. Biochemistry (1999) 38(50):16507-16513.
24. Keppler-Hafkemeyer A, Kreitman RJ, Pastan I: Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Int J Cancer (2000) 87(1):86-94.
25. Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I: Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J Biol Chem (1989) 264(24):14256-14261.
26. Kreitman RJ, Batra JK, Seetharam S, Chaudhary VK, FitzGerald DJ, Pastan I: Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: Relative importance of the two toxin disulfide bonds. Bioconjug Chem (1993) 4(2):112-120.
27. Kreitman RJ, Pastan I: Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J (1995) 307(Pt 1):29-37.
28. Seetharam S, Chaudhary VK, FitzGerald D, Pastan I: Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J Biol Chem (1991) 266(26):17376-17381.
29. Chaudhary VK, FitzGerald DJ, Pastan I: A proper amino terminus of diphtheria toxin is important for cytotoxicity. Biochem Biophys Res Commun (1991) 180(2):545-551.
30. Williams DP, Snider CE, Strom TB, Murphy JR: Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem (1990) 265(20):11885-11889.
31. Kreitman RJ: Getting plant toxins to fuse. Leuk Res (1997) 21(10):997-999.
32. 486IL-2) in patient with chronic lymphocytic leukaemia. Lancet (1991) 337(8750):1124-1125.
33. 486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood (1992) 79(10):2547-2554.
34. 486IL-2 in hematological cancers. Cancer Res (1993) 53(17):3930-3934.
35. 389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood (1998) 91(2):399-405.
36. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A et al: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol (2001) 19(2):376-388.
37. Duvic M, Kuzel T, Olsen E, Martin A, Foss F, Kim Y, Heald P, Bacha P, Nichols J, Cabanillas F: Quality of life is significantly improved in CTCL patients who responded to DAB389IL-2 (ONTAK) fusion protein. Blood (1998) 92(Suppl 1):2572a.
38. Railan D, Fivenson DP, Wittenberg G: Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma. J Am Acad Dermatol (2000) 43(2 Part 1):323-324.
39. 389-IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: Decreased frequency and severity with steroid premedication. Clin Lymphoma (2001) 1(4):298-302.
40. 389-IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: Algorithms. Clin Lymphoma (2000) 1 (Suppl 1):S51-S55.
41. Talpur R, Apisarnthanarax N, Ward S, Duvic M: Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk Lymphoma (2002) 43(1):121-126.
42. McGinnis KS, Shapiro M, Junkins Hopkins JM, Smith M, Lessin SR, Vittorio CC, Rook AH: Denileukin diftitox for the treatment of panniculitic lymphoma. Arch Dermatol (2002) 138(6):740-742.
43. 389-IL-2) in patients with severe psoriasis. J Am Acad Dermatol (2001) 45(6):871-881.
44. 389-IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene. Leuk Res (2002) 26(12):1077-1083.
45. Gorgun G, Foss F: Immunomodulatory effects of RXR rexinoids: Modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood (2002) 100(4):1399-1403.
46. Uchiyama TA, Broder S, Waldmann TA: A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac+ cells. J Immunol (1981) 126(4):1393-1397.
47. Yagura H, Tamaki T, Furitsu T, Tomiyama Y, Nishiura T, Tominaga N, Katagiri S, Yonezawa T, Tarui S: Demonstration of high-affinity interleukin-2 receptors on B-chronic lymphocytic leukemia cells: Functional and structural characterization. Blut (1990) 60(3):181-186.
48. Kodaka T, Uchiyama T, Ishikawa T, Kamio M, Onishi R, Itoh K, Hori T, Uchino H, Tsudo M, Araki K: Interleukin-2 receptor-β-chain (p70-75) expressed on leukemic cells from adult T-cell leukemia patients. Jpn J Cancer Res (1990) 81(9):902-908.
49. Weissman AM, Harford JB, Svetlik PB, Leonard WL, Depper JM, Waldmann TA, Greene WC, Klausner RD: Only high-affinity receptors for interleukin-2 mediate internalization of ligand. Proc Natl Acad Sci USA (1986) 83(5):1463-1466.
50. Chaudhary VK, Gallo MG, FitzGerald DJ, Pastan I: A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin. Proc Natl Acad Sci USA (1990) 87(23):9491-9494.
51. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, Lee T, Pope SH, Riordan GS, Whitlow M: Single-chain antigen-binding proteins. Science (1988) 242(4877):423-426.
52. Huston JS, Levinson D, Mudgett-Hunter M, Tai M-S, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, Oppermann H: Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA (1988) 85(16):5879-5883.
53. Kreitman RJ, Pastan I: Accumulation of a recombinant immunotoxin in a tumor in vivo: Less than 1000 molecules per cell is sufficient for complete responses. Cancer Res (1998) 58(5):968-975.
54. 125I-labeled antiTac single-chain Fv recombinant immunotoxin. J Nucl Med (2000) 41(4):755-762.
55. Kreitman RJ, Bailon P, Chaudhary VK, FitzGerald DJP, Pastan I: Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood (1994) 83(2):426-434.
56. Kreitman RJ, Pastan I: Targeting Pseudomonas exotoxin to hematologic malignancies. Semin Cancer Biol (1995) 6(5):297-306.
57. Kreitman RJ, Wilson WH, Robbins D, Margulies I, Stetler-Stevenson M, Waldmann TA, Pastan I: Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood (1999) 94(10):3340-3348.
58. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Waldmann TA, Pastan I: Phase I trial of recombinant immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) In patients with hematologic malignancies. J Clin Oncol (2000) 18(8):1622-1636.
59. Onda M, Kreitman RJ, Vasmatzis G, Lee B, Pastan I: Reduction of the nonspecific toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J Immunol (1999) 163(11):6072-6077.
60. Onda M, Willingham M, Wang QC, Kreitman RJ, Tsutsumi Y, Nagata S, Dinarello CA, Pastan I: Inhibition of TNFα produced by Kupffer cells protects against the non-specific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2. J Immunol (2000) 165(12):7150-7156.
61. Mavroudis DA, Jiang YZ, Hensel N, Lewalle P, Couriel D, Kreitman RJ, Pastan I, Barrett AJ: Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: A new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant (1996) 17(5):793-799.
62. Harris DT, Sakiestewa D, Lyons C, Kreitman RJ, Pastan I: Prevention of graft-versus-host disease (GVHD) by elimination of recipient-reactive donor T-cells with recombinant toxins that target the interleukin (IL)-2 receptor. Bone Marrow Transplant (1999) 23(2):137-144.
63. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, Iacucci R, Zei T, Martelli MP, Gambelunghe C et al: Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood (1994) 84(11):3948-3955.
64. Hertenstein B, Hampl W, Bunjes D, Wiesneth M, Duncker C, Koszinowski U, Heimpel H, Arnold R, Mertens T: In vivo/ex vivo T-cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant (1995) 15(3):387-393.
65. de Gast GC, Gratama JW, Verdonck LF, van Heugten JG, Zwaan FE, Phillips DI, Mudde GC: The influence of T-cell depletion on recovery of T-cell proliferation to herpesviruses and Candida after allogeneic bone marrow transplantation. Transplantation (1989) 48(1):111-115.
66. Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT, Drillich S, Schon G, Bohlen H, Tesch H, Hansmann ML, Barth S et al: A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood (1997) 89(2):403-410.
67. Schnell R, Vitetta E, Schindler J, Barth S, Winkler U, Borchmann P, Hansmann ML, Diehl V, Ghetie V, Engert A: Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. Leuk Lymphoma (1998) 30(5-6):525-537.
68. Schnell R, Vitetta E, Schindler J, Borchmann P, Barth S, Ghetie V, Hell K, Drillich S, Diehl V, Engert A: Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia (2000) 14(1):129-135.
69. Montagna D, Yvon E, Calcaterra V, Comoli P, Locatelli F, Maccario R, Fisher A, Cavazzana-Calvo M: Depletion of alloreactive T-cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood (1999) 93(10):3550-3557.
70. Barth S, Huhn M, Wels W, Diehl V, Engert A: Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines. Int J Mol Med (1998) 1(1):249-256.
71. Barth S, Huhn M, Matthey B, Schnell R, Tawadros S, Schinkothe T, Lorenzen J, Diehl V, Engert A: Recombinant anti-CD25 Immunotoxin RFT5(ScFv)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice. Int J Cancer (2000) 86(5):718-724.
72. Ghetie M-A, May RD, Till M, Uhr JW, Ghetie V, Knowles PP, Relf M, Brown A, Wallace PM, Janossy G, Amlot P et al: Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res (1988) 48(9):2610-2617.
73. Ghetie M-A, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES: Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B-cell lymphoma grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites. Cancer Res (1991) 51(21):5876-5880.
74. Bregni M, Siena S, Formosa A, Lappi DA, Martineau D, Malavasi F, Dorken B, Bonadonna G, Gianni AM: B-cell restricted saporin immunotoxins: Activity against B-cell lines and chronic lymphocytic leukemia cells. Blood (1989) 73(3):753-762.
75. Senderowicz AM, Vitetta E, Headlee D, Ghetie V, Uhr JW, Figg WD, Lush RM, Stetler-Stevenson M, Kershaw G, Kingma DW, Jaffe ES et al: Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann Intern Med (1997) 126(11):882-885.
76. Kreitman RJ, Hansen HJ, Jones AL, FitzGerald DJP, Goldenberg DM, Pastan I: Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Res (1993) 53(4):819-825.
77. Theuer CP, Kreitman RJ, FitzGerald DJ, Pastan I: Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity. Cancer Res (1993) 53(2):340-347.
78. Mansfield E, Chiron MF, Amlot P, Pastan I, FitzGerald DJ: Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells. Biochem Soc Trans (1997) 25(2):709-714.
79. Mansfield E, Amlot P, Pastan I, FitzGerald DJ: Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood (1997) 90(5):2020-2026.
80. Reiter Y, Brinkmann U, Kreitman RJ, Jung S-H, Lee B, Pastan I: Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry (1994) 33(18):5451-5459.
81. Reiter Y, Kreitman RJ, Brinkmann U, Pastan I: Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stablized anti-Tac Fv fragment and truncated Pseudomonas exotoxin. Int J Cancer (1994) 58(1):142-149.
82. Kreitman RJ, Wang QC, FitzGerald DJP, Pastan I: Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int J Cancer (1999) 81(1):148-155.
83. Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJP, Pastan I: Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res (2000) 6(4):1476-1487.
84. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med (2001) 345(4):241-247.
85. Flandrin G, Sigaux F, Sebahoun G, Bouffette P: Hairy cell leukemia: Clinical presentation and follow-up of 211 patients. Semin Oncol (1984) 11(4 Suppl 2):458-471.
86. Frassoldati A, Lamparelli T, Federico M, Annino L, Capnist G, Pagnucco G, Dini E, Resegotti L, Damasio EE, Silingardi V: Hairy cell leukemia: A clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. Leuk Lymphoma (1994) 13(3-4):307-316.
87. Tallman MS, Hakimian D, Kopecky KJ, Wheaton S, Wollins E, Foucar K, Cassileth PA, Habermann T, Grever M, Rowe JM, Peterson LC: Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res (1999) 5(7):1665-1670.
88. Kreitman RJ, Pastan I: Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either Pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells. Blood (1997) 90(1):252-259.
89. 388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res (2002) 8(5):1004-1013.
90. Posey JA, Khazaeli MB, Bookman MA, Nowrouzi A, Grizzle WE, Thornton J, Carey DE, Lorenz JM, Sing AP, Siegall CB, LoBuglio AF et al: A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res (2002) 8(10):3092-3099.
91. Pai-Scherf LH, Villa J, Pearson D, Watson T, Liu E, Willingham MC, Pastan I: Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res (1999) 5(9):2311-2315.
92. Kreitman RJ, Puri RK, Pastan I: A circularly permuted recombinant interleukin-4 toxin with increased activity. Proc Natl Acad Sci USA (1994) 91(15):6889-6893.
93. Kreitman RJ, Puri RK, Pastan I: Increased antitumor activity of a circularly permuted interleukin-4-toxin in mice with interleukin-4 receptor-bearing human carcinoma. Cancer Res (1995) 55(15):3357-3363.
94. Puri RK, Hoon DS, Leland P, Snoy P, Rand RW, Pastan I, Kreitman RJ: Preclinical development of a recombinant toxin containing circularly permuted interleukin-4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res (1996) 56(24):5631-5637.
95. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK: Intratumoral administration of a recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res (2000) 6(6):2157-2165.
96. Goldberg MR, Heimbrook DC, Russo P, Sarosdy MF, Greenberg RE, Giantonio BJ, Linehan WM, Walther M, Fisher HAG, Messing E, Crawford ED et al: Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin Cancer Res (1995) 1(1):57-61.
97. 280 generates the enzymatically active fragment which translocates to the cytosol. J Biol Chem (1992) 267(35):25396-25401.
98. 352 in membrane insertion and translocation by diphtheria toxin. Protein Sci (1996) 5(4):687-692.